Merck Keytruda Price and Early NSCLC Nod
Decision brief
Answer first · skim in under a minute
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment after resection and platinum-based chemotherapy in stage IB, II, and IIIA NSCLC. The decision adds another regulatory catalyst for Merck and creates a useful tracking point for investors and BD teams watching pembrolizumab in lung cancer.
Early-stage lung cancer is now part of Keytruda U.S. labeling. FDA January 26, 2023 adjuvant NSCLC decision and the Merck Keytruda price questions that follow hinge on KEYNOTE-091 disease-free survival after surgery and platinum chemotherapy.
Contents12 sections
Key Takeaways
- Adjuvant Keytruda covers stage IB (T2a >=4 cm), II, or IIIA NSCLC after resection and platinum chemotherapy.
- KEYNOTE-091 chemo-treated patients saw median DFS of 58.7 months versus 34.9 months with placebo.
- Treatment runs up to one year (200 mg IV every 3 weeks in the trial), which multiplies early-stage drug exposure.
- Merck Keytruda price realization will depend on adjuvant penetration, not only metastatic share.
What did FDA approve for adjuvant Keytruda in NSCLC?
On January 26, 2023, the FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a >=4 cm), II, or IIIA NSCLC.
Dosing in KEYNOTE-091 was pembrolizumab 200 mg or placebo every 3 weeks for up to 1 year. Of 1,177 randomized patients, 1,010 (86%) received adjuvant platinum chemotherapy after complete resection.
What did KEYNOTE-091 show on disease-free survival?
For patients who received adjuvant chemotherapy, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (hazard ratio 0.73; 95% CI 0.60-0.89).
- Trial ID: NCT02504372
- Nearly 24-month median DFS improvement in the chemo-treated group
- No PD-L1 selection required on the adjuvant label
In an exploratory subgroup of 167 patients who did not receive adjuvant chemotherapy, the DFS hazard ratio was 1.25 (95% CI 0.76-2.05). That subgroup is not a win.
Why do early-stage DFS numbers matter clinically?
Moving PD-1 blockade before metastatic relapse can prevent recurrence events that otherwise generate later-line therapy. The chemo-treated KEYNOTE-091 cohort is the labeled population that supports that claim.
Stage IB tumors must meet the T2a >=4 cm threshold. Smaller resected tumors outside that definition are not covered by this indication text.
How should teams think about Merck Keytruda price here?
Early-stage adjuvant courses are time-limited but can reach patients who previously generated zero Keytruda revenue. Volume upside and policy downside both grow.
Use company filings and ASP files when modeling Merck Keytruda price. FDA approval pages confirm clinical facts only.
Which safety signals did FDA highlight?
FDA noted adverse reactions generally similar to single-agent Keytruda in NSCLC, with hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%) called out. Two fatal myocarditis events occurred.
Immune-related toxicity management affects real-world completion of the up-to-one-year adjuvant course and therefore realized volume.
What remains unproven after the 2023 label?
Overall survival maturity in routine care, competing perioperative regimens, and Medicare price-negotiation outcomes are not settled by the approval memo alone.
Public FDA pages do not publish a Keytruda WAC. Delete unsourced Merck Keytruda price dollar figures rather than inventing them.
How should teams document claims for compliance?
Copy efficacy numbers only from FDA pages or peer-reviewed publications. When an IR release rounds a hazard ratio, prefer the FDA confidence interval in diligence decks.
Keep a source table with URL, access date, and the exact sentence supporting each percentage. That habit prevents AI citation drift and auditor failures.
What operational questions follow the clinical catalyst?
Ask whether infusion chairs, biomarker testing, and adverse-event pathways exist before modeling peak share. Clinical wins stall when operations cannot deliver the labeled regimen.
For pricing keywords, separate list price, net price, and policy risk. Invented WAC figures are worse than omitting price entirely.
Related NovaPharma coverage
- FDA Approves Keytruda Adjuvant NSCLC (Merck)
- Medicare price rule, Keytruda and Opdivo subcutaneous launches
- Merck Harpoon Therapeutics acquisition oncology pipeline
Frequently Asked Questions
When did FDA approve Keytruda for adjuvant NSCLC?
On January 26, 2023, FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a >=4 cm), II, or IIIA NSCLC.
What trial supported adjuvant Keytruda in NSCLC?
KEYNOTE-091 (NCT02504372) randomized 1,177 patients. Among the 1,010 who received adjuvant platinum chemotherapy, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (HR 0.73; 95% CI 0.60-0.89).
Does adjuvant Keytruda require PD-L1 positivity?
FDA approval text does not require PD-L1 selection for this adjuvant indication. The chemotherapy-treated subgroup benefit was reported regardless of PD-L1 expression.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pembrolizumab.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- RYBREVANT® Access and Reimbursement Guide Overview — Explore key insights on RYBREVANT® reimbursement and access strategies for NSCLC treatment.…
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…